Multisystem inflammatory syndrome in a young adult successfully treated with plasmapheresis, immunoglobulins, and corticosteroids: a case report

Srećković, Miodrag; Marjanovic, Ruzica Radojevic; Jovicić, Biljana Popovska; Janković, Slobodan M.; Medovic, Rasa; Cvetkovic, Milica; Lazarevic, Tatjana; Milosavljević, Mirjana; Simović, Stefan; Vučić, Rada

doi:10.1016/j.ijid.2022.07.059

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 TPE has also been successfully used for the treatment of inflammatory syndromes after SARS-CoV-2-infections in adults and children. 14,22 As a result, many authors consider TPE to be the last therapeutic resort when standard (immunomodulatory) therapy fails. The use of TPE in EVALI has not been reported to our knowledge and more study is certainly necessary.…”

Section: Discussionmentioning

confidence: 99%

“…The results of a meta-analysis indicated that TPE can reduce mortality in severe COVID-19 but with no change in ICU length of stay 21 . TPE has also been successfully used for the treatment of inflammatory syndromes after SARS-CoV-2-infections in adults and children 14,22 . As a result, many authors consider TPE to be the last therapeutic resort when standard (immunomodulatory) therapy fails.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Plasmapheresis as therapeutic option in a 16-year-old with EVALI

Gaik,

Arndt,

Mand

et al. 2024

European Journal of Anaesthesiology

View full text Add to dashboard Cite

Since 2019 when a cluster of cases with acute respiratory distress syndrome (ARDS) associated with e-cigarettes in the United States was reported, there have been increasing numbers of reports. Electronic-cigarette or Vaping Use-associated Lung Injury (EVALI) represents a recent entity of respiratory clinical syndromes, primarily in young adults. We report a previously healthy 16-year-old boy who developed severe ARDS following a brief nonspecific prodromal phase after excessive consumption of e-cigarettes. Despite maximum intensive care therapy, including several weeks of venovenous extracorporeal membrane oxygenation, plasmapheresis and repeated administration of immunoglobulins seemed the only way to achieve therapeutic success. Although many case reports have been published, to our knowledge, there are none to date on the therapeutic use of plasmaphoresis in severe EVALI. This case highlights the clinical features of EVALI and the diagnostic dilemma that can arise with EVALI occurring against the background of an expired SARS-CoV-2 infection, with a paediatric inflammatory syndrome (PIMS) as differential diagnosis. EVALI is a diagnosis of exclusion, and the medical history of vaping and e-cigarette use can provide valuable clues. Ethical approval for this case report (protocol number 23–145 RS) was provided by the Ethical Committee of the Department of Medicine, Philipps-Universität Marburg, Germany on 13th of June 2023. Written informed consent to publish this case and the associated images was obtained from the patient and his mother.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%